A Randomized, Open-label, Active-controlled, 3-arm Parallel-group, 26-week Study Comparing the Efficacy and Safety of Lixisenatide to That of Insulin Glulisine Once Daily and Insulin Glulisine Three Times Daily in Patients With Type 2 Diabetes Insufficiently Controlled With Insulin Glargine With or Without Metformin

Trial Profile

A Randomized, Open-label, Active-controlled, 3-arm Parallel-group, 26-week Study Comparing the Efficacy and Safety of Lixisenatide to That of Insulin Glulisine Once Daily and Insulin Glulisine Three Times Daily in Patients With Type 2 Diabetes Insufficiently Controlled With Insulin Glargine With or Without Metformin

Completed
Phase of Trial: Phase III

Latest Information Update: 15 Sep 2017

At a glance

  • Drugs Lixisenatide (Primary) ; Insulin glargine; Insulin glulisine; Metformin
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms GetGoal-Duo-2
  • Sponsors Sanofi
  • Most Recent Events

    • 15 Sep 2017 Results of exploratory analysis assessing if iGlarLixi is more effective and better tolerated than sequential injections of iGlar and Lixi using patient data from NCT02058160 and NCT01768559 trials presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes
    • 13 Jun 2017 Results of a propensity score-matched analysis to Compare LixiLan-L and GetGoal Duo-2 trials presented at the 77th Annual Scientific Sessions of the American Diabetes Association
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top